



De Novo Drug Design for Emerging and Reemerging Viruses

Guest Editors:

Prof. Dr. Ke Xu

State Key Laboratory of Virology,
College of Life Sciences, Wuhan
University, Wuhan, China

Prof. Dr. Yu Chen

State Key Laboratory of Virology,
College of Life Sciences, Wuhan
University, Wuhan 430072, China

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editors

Dear Colleagues

For emerging and re-emerging viruses that are zoonotic in origin, de novo drug design targeting viral proteins and viral life cycles provides an efficient approach to inhibit virus replication and therefore cure the disease. A greater understanding of the basic virology of these viruses, including virus entry, cellular receptors, virus–cell fusion, viral RNA or DNA synthesis and duplication, and virus assembly and release, has resulted in many successful antiviral drugs in the last 20 years.

This Special Issue is designed to provide an up-to-date review of the latest progress and technologies in de novo drug design (such drugs can be small molecular, peptides, antibodies, etc.) for emerging and re-emerging viruses targeting viral or host proteins based on their protein structures or their unique functions in the viral life cycle.

Prof. Dr. Ke Xu
Prof. Dr. Yu Chen
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication
Program, Center for Cancer
Research, National Cancer
Institute, Frederick, MD 21702-
1201, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.**

Journal Rank: JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Contact Us

Viruses Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/viruses
viruses@mdpi.com
[X@VirusesMDPI](https://twitter.com/VirusesMDPI)